NVAX : Summary for Novavax, Inc. - Yahoo Finance

Canadian Markets closed

Novavax, Inc. (NVAX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.35-0.02 (-1.46%)
At close: 4:00PM EST

1.35 0.00 (0.00%)
After hours: 4:31PM EST

People also watch
BCRXINOHEBDVAXARRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.37
Open1.38
Bid1.35 x 1000
Ask1.37 x 12500
Day's Range1.34 - 1.40
52 Week Range1.16 - 8.49
Volume3,920,314
Avg. Volume8,042,380
Market Cap366.18M
Beta1.95
PE Ratio (TTM)-1.21
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journalsyesterday

    Novavax starts new clinical trial in bid to prove failed RSV vaccine

    Novavax isn't ready to give up just yet on what was once its most promising vaccine candidate — turned stunning failure last fall . On Thursday, Gaithersburg-based Novavax (NVAX) announced it started a new phase 2 clinical trial of the product, a vaccine candidate for respiratory synctial virus, or RSV, in older adults. The trial, which will enroll up to 300 older adults in the southern hemisphere, is meant to test the safety and ability of the vaccine candidate to provoke an immune response to both one- and two-dose regimens.

  • GlobeNewswireyesterday

    Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults

    GAITHERSBURG, Md., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine ...

  • GlobeNewswireyesterday

    Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults

    GAITHERSBURG, Md., Jan. 19, 2017-- Novavax, Inc. today announced the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate in older adults.. ...